Malignant peripheral nerve sheath tumors: a report from children's oncology group study ARST0332
Topic overview
Children's Oncology Group study ARST0332 evaluated risk-adapted treatment for MPNST in 58 patients, combining surgery, radiation, and chemotherapy. Low-risk patients achieved 87% 5-year survival, while metastatic disease had universally poor outcomes regardless of NF-1 status, highlighting the need for novel therapies.
Key takeaways
- Low-risk MPNST patients achieved 87% 5-year survival with risk-adapted multimodal therapy combining surgery, radiation, and chemotherapy.
- Neoadjuvant chemotherapy showed limited efficacy with only 23% objective response rate; 32% progressed during treatment.
- Metastatic MPNST had universally poor outcomes (0% 5-year EFS) regardless of treatment approach, requiring novel therapeutic strategies.
- NF-1 status did not impact survival outcomes, contrary to some prior reports suggesting worse prognosis in NF-1 patients.
- Complete or near-complete surgical resection (R0/R1) was a critical prognostic factor for event-free and overall survival.
Comments